InvestSMART

Pilbara Gold Limited (ASX: PGL) - Announcements

Current share price for PGL : $0.525 0.01 (1.87%)+

ASX company news and announcements for Pilbara Gold Limited (PGL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pilbara Gold Limited (PGL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pilbara Gold Limited (PGL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pilbara Gold Limited (PGL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$123 Update to Interim Phase III Results for PI-88 29 Jul 2014 5:24PM $0.230 $0.525 risen by 128.26%
$123 Interim Phase III Results for PI-88 28 Jul 2014 8:53AM $0.295 $0.525 risen by 77.97%
$123 EPO to Grant Sulfated Oligosaccharide Derivatives Patent 21 Jul 2014 9:32AM $0.800 $0.525 fallen by 34.38%
$123 PG545 Phase 1 Clinical Trial Update 15 May 2014 9:01AM $0.990 $0.525 fallen by 46.97%
$123 Changes to Management & Corporate Office Address 14 May 2014 8:26AM $1.025 $0.525 fallen by 48.78%
$123 Medigen Expects PI-88 Interim Patient Data in May 2014 8 May 2014 12:05PM $0.935 $0.525 fallen by 43.85%
$123 Medigen Engages PharmaSynth to Manufacture PI-88 29 Apr 2014 12:31PM $0.990 $0.525 fallen by 46.97%
$123 Notice of Allowance of US patent for PG545 28 Apr 2014 8:27AM $0.960 $0.525 fallen by 45.31%
$123 PG545 Data Presented at AACR Conference 9 Apr 2014 9:47AM $0.880 $0.525 fallen by 40.34%
$123 Response to ASX Price Query 17 Mar 2014 9:24AM $0.895 $0.525 fallen by 41.34%
$123 Half Yearly Report and Accounts 27 Feb 2014 5:27PM $0.500 $0.525 risen by 5%
$123 Response to ASX Price Query 30 Jan 2014 2:11PM $0.540 $0.525 fallen by 2.78%
$123 PATRON Trial Completes Patient Recruitment 30 Dec 2013 4:24PM $0.220 $0.525 risen by 138.64%
$123 R&D Tax Incentive Refund 17 Dec 2013 5:43PM $0.200 $0.525 risen by 162.50%
$123 Beta Therapeutics Assignment Agreement 3 Dec 2013 3:30PM $0.230 $0.525 risen by 128.26%
$123 2013 Annual General Meeting Address 28 Nov 2013 2:10PM $0.210 $0.525 risen by 150%
$123 PG545 Phase 1 Cancer Trial Update 29 Oct 2013 2:11PM $0.220 $0.525 risen by 138.64%
$123 Change to Acting Managing Director's Terms of Employment 21 Oct 2013 12:24PM $0.200 $0.525 risen by 162.50%
$123 Preliminary Final Report 27 Aug 2013 6:21PM $0.185 $0.525 risen by 183.78%
$123 Update on PG545 Preclinical Program 22 Aug 2013 10:08AM $0.200 $0.525 risen by 162.50%
$123 Board and Senior Management Changes 12 Jul 2013 4:37PM $0.195 $0.525 risen by 169.23%
$123 Share Placement & Appendix 3B 27 May 2013 8:27AM $0.215 $0.525 risen by 144.19%
$123 Offer Document - Non-Renounceable Rights Issue 17 Apr 2013 1:59PM $0.200 $0.525 risen by 162.50%
$123 Non Renounceable Pro Rata Rights Issue 16 Apr 2013 4:24PM $0.200 $0.525 risen by 162.50%
$123 Progen Pharmaceuticals signs PG545 License 1 Mar 2013 3:52PM $0.220 $0.525 risen by 138.64%

426 - 450 of 580 results

Page 18 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.